# Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC

> **NCT07436663** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Tanta University** · enrollment: 150 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
- **DRUG:** Sitagliptin (DPP4 inhibitor)
- **OTHER:** Standard Care (in control arm)

## Key facts

- **NCT ID:** NCT07436663
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2027-11-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07436663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07436663, "Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07436663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*